Key result
Managing incretin-based obesity therapy adverse effects requires targeted clinical mitigation strategies.
Answers are grounded in this paper and cite their sources.
This review outlines optimal strategies for managing the adverse effects of incretin-based medications such as semaglutide and tirzepatide used for obesity.
This JAMA Insights explores optimal strategies for managing the adverse effects associated with incretin-based medications for obesity, including semaglutide and tirzepatide.
No takes yet. Share an insight, caveat, or question.
Kushner et al. (2025) studied this question. Incretin-based medications for obesity, including semaglutide and tirzepatide, are associated with adverse effects that require optimal management strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: